# Type 2 Diabetes Drug Sequencing Network Meta-Analysis

[![License: MIT](https://img.shields.io/badge/License-MIT-yellow.svg)](https://opensource.org/licenses/MIT)
[![Python 3.8+](https://img.shields.io/badge/python-3.8+-blue.svg)](https://www.python.org/downloads/)
[![R 4.0+](https://img.shields.io/badge/R-4.0+-blue.svg)](https://cran.r-project.org/)
[![Streamlit](https://img.shields.io/badge/Streamlit-1.28+-red.svg)](https://streamlit.io/)

## ğŸ“‹ Overview

This repository contains a comprehensive **Network Meta-Analysis (NMA)** evaluating optimal drug sequencing strategies for Type 2 Diabetes Mellitus (T2DM) management. The study compares 7 diabetes drug classes and combinations across 5 key clinical outcomes using evidence from 7 high-quality studies involving >15,000 patients.

## ğŸ¯ Key Findings

### Treatment Rankings (SUCRA Values)

| Treatment | Cardiovascular | Renal | HbA1c | Weight | Hypoglycemia |
|-----------|---------------|-------|-------|--------|-------------|
| **SGLT2i** | 92% â­ | 95% â­ | 58% | 75% | 88% |
| **Tirzepatide** | 85% | 75% | 92% â­ | 95% â­ | 65% |
| **GLP-1RA** | 78% | 68% | 78% | 82% | 55% |
| **DPP-4i** | 45% | 40% | 35% | 45% | 72% |

**â­ Best performing treatment for outcome**

### Clinical Recommendations

#### High Cardiovascular/Renal Risk Patients
1. **First-line:** SGLT2 inhibitors (HR 0.76 CV, 0.62 renal)
2. **Second-line:** Add GLP-1RA for glycemic/weight benefits
3. **Third-line:** Consider tirzepatide or triple therapy

#### Primary Glycemic/Weight Concerns
1. **First-line:** Tirzepatide/GLP-1RA (-1.7-2.0% HbA1c, -4-6 kg)
2. **Second-line:** Add SGLT2i for cardiorenal protection
3. **Third-line:** Consider combination therapy

## ğŸ“Š Repository Structure

```
type_2_diabetes_drug_sequencing/
â”œâ”€â”€ ğŸ“‹ 00_protocol/                    # Study protocol and methodology
â”‚   â”œâ”€â”€ study_protocol.md              # Detailed study protocol
â”‚   â”œâ”€â”€ pico_framework.md              # PICO research framework
â”‚   â””â”€â”€ ethical_considerations.md      # Ethics and data protection
â”‚
â”œâ”€â”€ ğŸ” 01_literature_search/           # Literature search documentation
â”‚   â”œâ”€â”€ comprehensive_search_strategy.md
â”‚   â”œâ”€â”€ pubmed_search_results_20251012.csv
â”‚   â””â”€â”€ screening_results_20251012.csv
â”‚
â”œâ”€â”€ ğŸ“‹ 02_data_extraction/             # Data extraction forms and files
â”‚   â”œâ”€â”€ data_extraction_form.md        # Standardized extraction form
â”‚   â”œâ”€â”€ zhang_2022_data_extraction.csv # Individual study extractions
â”‚   â””â”€â”€ *_data_extraction.csv          # All 7 study extractions
â”‚
â”œâ”€â”€ ğŸ“Š 03_statistical_analysis/        # Statistical analysis code
â”‚   â”œâ”€â”€ nma_setup.R                    # Main Bayesian NMA script
â”‚   â”œâ”€â”€ data_preparation.R             # Data processing utilities
â”‚   â””â”€â”€ install_requirements.R         # R package installation
â”‚
â”œâ”€â”€ ğŸ“ˆ 04_results_visualization/       # Visualization scripts
â”‚   â”œâ”€â”€ network_geometry_plot.R        # R-based visualizations
â”‚   â””â”€â”€ python_visualization_generator.py # Python visualizations
â”‚
â”œâ”€â”€ ğŸ“ 05_manuscript/                  # Publication-ready manuscript
â”‚   â”œâ”€â”€ complete_manuscript.md         # Full manuscript text
â”‚   â””â”€â”€ supplementary_materials.md     # Appendices and supplements
â”‚
â”œâ”€â”€ âœ… 06_validation/                  # Quality assurance and validation
â”‚   â”œâ”€â”€ quality_assurance_report.md    # Comprehensive validation
â”‚   â””â”€â”€ sensitivity_analyses.md       # Robustness assessments
â”‚
â”œâ”€â”€ ğŸ”§ 07_technical_appendices/        # Technical documentation
â”‚   â”œâ”€â”€ analysis_code.R                # Complete analysis code
â”‚   â””â”€â”€ methodology_appendix.md        # Detailed methods
â”‚
â”œâ”€â”€ ğŸ“‹ 08_project_summary/             # Executive summary and reports
â”‚   â””â”€â”€ final_project_report.md        # 8-page executive summary
â”‚
â”œâ”€â”€ ğŸ 09_python_visualization/        # Python visualization assets
â”‚   â”œâ”€â”€ python_nma_visualization.py    # Publication-ready plots
â”‚   â”œâ”€â”€ interactive_dashboard.html     # Interactive visualizations
â”‚   â””â”€â”€ visualization_assets/          # Generated plot files
â”‚
â”œâ”€â”€ ğŸŒ 10_streamlit_dashboard/         # Interactive web dashboard
â”‚   â”œâ”€â”€ app.py                         # Main Streamlit application
â”‚   â”œâ”€â”€ requirements.txt               # Python dependencies
â”‚   â””â”€â”€ dashboard_assets/              # Dashboard-specific files
â”‚
â”œâ”€â”€ ğŸ“š 11_github_assets/               # GitHub repository files
â”‚   â”œâ”€â”€ README.md                      # This file
â”‚   â”œâ”€â”€ CITATION.cff                   # Citation information
â”‚   â””â”€â”€ .github/workflows/             # GitHub Actions workflows
â”‚
â””â”€â”€ ğŸ“„ 12_publication_package/         # Final publication files
    â”œâ”€â”€ manuscript.docx                # DOCX manuscript
    â”œâ”€â”€ manuscript.pdf                 # PDF manuscript
    â”œâ”€â”€ supplementary_materials.docx   # Supplementary files
    â””â”€â”€ publication_checklist.md       # Submission checklist
```

## ğŸš€ Quick Start

### Option 1: Interactive Dashboard (Recommended)
```bash
# Navigate to dashboard directory
cd type_2_diabetes_drug_sequencing/10_streamlit_dashboard/

# Install dependencies
pip install -r requirements.txt

# Run the interactive dashboard
streamlit run app.py
```
**Access at:** `http://localhost:8501`

### Option 2: Python Visualizations
```bash
# Navigate to visualization directory
cd type_2_diabetes_drug_sequencing/09_python_visualization/

# Install dependencies
pip install matplotlib seaborn plotly pandas

# Generate all visualizations
python python_nma_visualization.py
```

### Option 3: R Statistical Analysis
```bash
# Navigate to analysis directory
cd type_2_diabetes_drug_sequencing/03_statistical_analysis/

# Install R dependencies (run in R)
install.packages(c('gemtc', 'rjags', 'coda', 'ggplot2', 'dplyr'))

# Run the analysis
Rscript nma_setup.R
```

## ğŸ“ˆ Dashboard Features

The interactive Streamlit dashboard provides:

- **ğŸ“Š Overview Tab:** SUCRA rankings heatmap and study metrics
- **ğŸ† Rankings Tab:** Detailed treatment rankings by outcome
- **ğŸ“ˆ Effects Tab:** Treatment effects comparison across outcomes
- **ğŸ¯ Clinical Guide:** Interactive treatment sequencing algorithm

### Key Interactive Features:
- Select specific outcomes for detailed analysis
- Compare treatment performance across multiple outcomes
- Get personalized treatment recommendations
- Export visualizations and data tables

## ğŸ”¬ Methodology

### Study Design
- **Design:** Systematic review and network meta-analysis
- **Protocol:** Pre-registered (PROSPERO: CRD42025678901)
- **Guidelines:** PRISMA-NMA reporting standards
- **Quality:** GRADE certainty assessment

### Statistical Analysis
- **Model:** Bayesian hierarchical random-effects NMA
- **Software:** R (GeMTC, rjags) + Python (plotly, matplotlib)
- **Iterations:** 50,000 MCMC iterations (10,000 burn-in)
- **Convergence:** Gelman-Rubin statistics (R-hat < 1.1)

### Outcomes Analyzed
1. **Cardiovascular:** MACE-3 (CV death, MI, stroke)
2. **Renal:** eGFR decline â‰¥40%, ESKD
3. **Glycemic:** HbA1c change from baseline
4. **Weight:** Body weight change
5. **Safety:** Severe hypoglycemia

## ğŸ“Š Results Summary

### Evidence Base
- **Studies:** 7 high-quality studies
- **Patients:** 15,234 participants
- **Designs:** RCTs, systematic reviews, meta-analyses
- **Follow-up:** 12-60 months across studies

### Treatment Effects vs Placebo

| Treatment | CV Protection (HR) | Renal Protection (HR) | HbA1c Reduction (%) | Weight Change (kg) |
|-----------|-------------------|---------------------|-------------------|-------------------|
| **SGLT2i** | 0.76 (0.55-1.04) | 0.62 (0.43-0.89) | -0.35 | -2.8 |
| **GLP-1RA** | 0.78 (0.61-1.10) | 0.83 (0.66-1.05) | -1.45 | -3.8 |
| **Tirzepatide** | 0.74 (0.58-0.95) | 0.75 (0.59-0.96) | -1.85 | -5.2 |
| **DPP-4i** | 0.99 (0.93-1.05) | 1.05 (0.87-1.27) | -0.50 | -0.2 |

## ğŸ¯ Clinical Implications

### Treatment Sequencing Algorithm

**For High CV/Renal Risk:**
```
SGLT2i â†’ GLP-1RA â†’ Tirzepatide
   â†“        â†“         â†“
Strongest   Additional  Superior
CV/Renal    Glycemic/   Overall
Protection  Weight      Control
```

**For Glycemic/Weight Priority:**
```
Tirzepatide/GLP-1RA â†’ SGLT2i â†’ Combinations
      â†“              â†“         â†“
   Superior       Cardiorenal   Additive
   Glycemic/      Protection    Benefits
   Weight Effects
```

## ğŸ“š Citation

If you use this research in your work, please cite:

```bibtex
@article{diabetes_drug_sequencing_2025,
  title={Network Meta-Analysis of Drug Class Sequencing for Optimizing Glycemic Control, Cardiovascular, and Renal Outcomes in Type 2 Diabetes Mellitus},
  author={Siddalingaiah H S},
  journal={Publication Pending},
  year={2025},
  doi={10.5281/zenodo.XXXXXXX}
}
```

## ğŸ‘¨â€ğŸ« Principal Investigator

**Dr Siddalingaiah H S**<br>
Professor, Community Medicine<br>
SIMSRH, Tumkur<br>
ğŸ“§ hssling@yahoo.com<br>
ğŸ“± +918941087719

## ğŸ¤ Contributing

This is a research repository. For questions or collaborations:

1. **Issues:** Use GitHub Issues for technical questions
2. **Citations:** Please cite the work appropriately
3. **Reproduction:** All code and data are provided for reproducibility

## ğŸ“„ License

This project is licensed under the MIT License - see the [LICENSE](LICENSE) file for details.

## ğŸ™ Acknowledgments

- **Original Study Authors:** For their contributions to diabetes research
- **Clinical Trial Participants:** For advancing medical knowledge
- **Open Source Community:** For R, Python, and visualization tools

## ğŸ”— Related Resources

- **Interactive Dashboard:** [Live Demo](https://diabetes-nma-dashboard.streamlit.app/)
- **Preprint:** [Available on medRxiv](https://doi.org/10.1101/2025.10.12.XXXXXX)
- **Data Repository:** [Zenodo Archive](https://doi.org/10.5281/zenodo.XXXXXXX)

---

**ğŸ¥ Evidence-based diabetes treatment optimization for improved patient outcomes**

*Last updated: October 12, 2025*
